BTK/PD-1 blockade for treatment of Richter's transformation
Mené sur 144 patients atteints d'un lymphome non hodgkinien récidivant ou d'une leucémie lymphocytaire chronique, cet essai de phase I/IIa évalue l'activité antitumorale préliminaire, la dose maximale tolérée et la toxicité de l'ibrutinib en combinaison avec le nivolumab
Richter's transformation describes the development of aggressive lymphoma in patients with chronic lymphocytic leukaemia. It occurs in approximately 2–10% of patients with chronic lymphocytic leukaemia, with an annual transformation rate of 0·5–1%. 1
Most Richter's transformations are from chronic lymphocytic leukaemia to the activated B-cell subtype of diffuse large B-cell lymphoma, and are rarely to Hodgkin lymphoma. Despite striking breakthroughs in the overall treatment landscape of chronic lymphocytic leukaemia, 2 Richter's transformation remains a devastating disease that represents an area of true, dire, unmet need. A pooled analysis of anthracycline-based or platinum-based chemotherapy showed low complete remission (20–30%) with overall survival of approximately 8 months. 1
Responses to chemotherapy are typically short-lived, leading to the common practice of consolidating responses with stem-cell transplantation in the few patients who are in complete remission and eligible
The Lancet Haematology , commentaire, 2018